SCHEMBL4742308

SCHEMBL4742308

CCN(CC)CCCC(Nc1ccnc2cc(F)ccc12)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.56
CHRM4 P08173 2/20 0.56
CHRM5 P08912 2/20 0.56
ADRA2A P08913 2/20 0.56
CHRM1 P11229 2/20 0.56
ADRA2B P18089 2/20 0.56
ADRA2C P18825 2/20 0.56
CHRM3 P20309 2/20 0.56
KCNH2 Q12809 2/20 0.56
TMEM97 Q5BJF2 2/20 0.56
SIGMAR1 Q99720 2/20 0.56
ACE2 Q9BYF1 2/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
PRNP P04156 1/20 0.56
APP P05067 1/20 0.56
NQO2 P16083 1/20 0.56
MTOR P42345 1/20 0.56
NR4A2 P43354 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745970 0.94 TMEM97 (0.60) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL708741 0.90 CHRM2 (0.56) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL707397 0.89 KCNH2 (0.72) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL1695371 0.86 CACNA2D1 (0.51) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL4746028 0.85 CHRM2 (0.76) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL29523096 0.85 CHRM2 (0.76) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL709193 0.84 KCNH2 (0.60) CHRM2CHRM4CHRM5ADRA2ACHRM1
Phosphoric Acid SCHEMBL5071882 0.84 KDM4E (0.79) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL710004 0.83 CHRM2 (0.76) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL4959781 0.80 CHRM2 (0.56) CHRM2CHRM4CHRM5ADRA2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581167-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS ALPHA RES GROUP LLC (US) 2008-10-29 EP claimed
JP-2006514917-A 2006-05-18 JP claimed
EP-1581167-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS Alpha Research Group, LLC (US) 2005-10-05 EP claimed
US-20040229908-A1 Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias Greenlee, Winner and Sullivan, P.C. 2004-11-18 US claimed
WO-2004004660-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS ALPHA RESEARCH GROUP, L.L.C. (US) 2004-01-15 WO claimed
US-20020198231-A1 Compositions and methods for the treatment of Parkinson's disease Greenlee, Winner and Sullivan, P.C. 2002-12-26 US claimed
US-20240228646-A9 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF AVIDITY BIOSCIENCES INC (US) 2024-07-11 US disclosed
US-12006499-B2 Una amidites and uses thereof AVIDITY BIOSCIENCES, INC. (US) 2024-06-11 US disclosed
US-11999955-B2 Compositions and methods of treating facioscapulohumeral muscular dystrophy AVIDITY BIOSCIENCES, INC. (US) 2024-06-04 US disclosed
US-20240132611-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF Atrium Therapeutics, Inc. 2024-04-25 US disclosed
US-20240132610-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AVIDITY BIOSCIENCES, INC. 2024-04-25 US disclosed
US-20240124600-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AVIDITY BIOSCIENCES, INC. 2024-04-18 US disclosed
US-11912779-B2 Compositions and methods of treating facioscapulohumeral muscular dystrophy AVIDITY BIOSCIENCES, INC. (US) 2024-02-27 US disclosed
US-20080051323-A1 Chloroquine drug compositions and methods for their synthesis KOSAK KENNETH M 2008-02-28 US disclosed
US-20070166281-A1 Chloroquine coupled antibodies and other proteins with methods for their synthesis KOSAK KENNETH M 2007-07-19 US disclosed
WO-2007040469-A2 CHLOROQUINE COUPLED COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS KOSAK KEN M (US) 2007-04-12 WO disclosed
US-20070060499-A1 Chloroquine combination drugs and methods for their synthesis KOSAK KENNETH M 2007-03-15 US disclosed
US-20060040879-A1 Chloroquine coupled nucleic acids and methods for their synthesis KOSAK KENNETH M 2006-02-23 US disclosed
US-20040229908-A1 Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias Greenlee, Winner and Sullivan, P.C. 2004-11-18 US disclosed
US-20020198231-A1 Compositions and methods for the treatment of Parkinson's disease Greenlee, Winner and Sullivan, P.C. 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124600-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY MYOF, MTPN, PYGM CHRM2 3349/4885CHRM4 3301/4885CHRM5 3434/4885
US-20070166281-A1 Chloroquine coupled antibodies and other proteins with methods for their synthesis GPR119, CLTA, CHMP4B CHRM2 3747/4885CHRM4 3447/4885CHRM5 3544/4885
US-20070060499-A1 Chloroquine combination drugs and methods for their synthesis CHMP4B, CTSA, CLTA CHRM2 2645/4885CHRM4 1807/4885CHRM5 1926/4885
US-20080051323-A1 Chloroquine drug compositions and methods for their synthesis CHMP4B, CTSA, CLTA CHRM2 2827/4885CHRM4 2181/4885CHRM5 2013/4885
US-11912779-B2 Compositions and methods of treating facioscapulohumeral muscular dystrophy MYOF, MTPN, PYGM CHRM2 3349/4885CHRM4 3301/4885CHRM5 3434/4885
US-20060040879-A1 Chloroquine coupled nucleic acids and methods for their synthesis TLR9, TLR3, EXOSC5 CHRM2 3882/4885CHRM4 3099/4885CHRM5 3556/4885
US-20240132611-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF TFRC, FOLR1, CD47 CHRM2 4057/4885CHRM4 4342/4885CHRM5 3910/4885
US-20240132610-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY MYOF, MTPN, PYGM CHRM2 3349/4885CHRM4 3301/4885CHRM5 3434/4885
US-12006499-B2 Una amidites and uses thereof NCL, PNP, NASP CHRM2 2890/4885CHRM4 3546/4885CHRM5 3030/4885
US-20240228646-A9 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF TFRC, FOLR1, CD47 CHRM2 4057/4885CHRM4 4342/4885CHRM5 3910/4885
US-11999955-B2 Compositions and methods of treating facioscapulohumeral muscular dystrophy MTPN, MYOF, CPT1B CHRM2 3455/4885CHRM4 3472/4885CHRM5 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.